Work

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Year: 2020

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2020-142065

Authors: Milos D. Miljkovic, Kevin C Conlon, Jennifer Albert, Deborah Allen, Thomas A. Waldmann

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, United States Food and Drug Administration

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3096297243

FWCI: 0.329

Cites:

Cited by: 2

Related to: 10